PubMed

Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.

PMID: 29714564 · 2018-01-31

C, r, a, i, g, , A, , G, a, r, m, e, n, d, i, a, ;, , N, e, e, r, a, , B, h, a, n, s, a, l, i, ;, , P, u, r, n, i, m, a, , M, a, d, h, i, v, a, n, a, n

학술지Therapeutic innovation & regulatory science

연도2018-01-31

PMID29714564

초록

The US Food and Drug Administration (FDA) ensures that clinical trials meet regulatory and ethical standards through inspections of researchers, also known as clinical investigators. Inspections with significant regulatory/ethical violations may result in regulatory actions, such as a warning letter or a Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE). Objectives included the standardization of regulatory violation themes cited by the FDA for novel analys

공식 출처

PubMed에서 보기 →

데이터는 PubMed / NCBI에서 제공됩니다. 전문과 최신 정보는 반드시 공식 기록을 확인하세요.